Zacks Small-Cap Research (Zacks SCR) published a report last week on VolitionRx, which develops and sells early-detection tests for serious diseases. It set a target price for the stock of $3.60 per share, five times the closing price as of Friday, August 30, noting the company’s expanding distribution network and…